EP 2313382 A1 20110427 - 5-(4-METHANESULFONYL-PHENYL)-THIAZOLE DERIVATIVES FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATORY DISEASES
Title (en)
5-(4-METHANESULFONYL-PHENYL)-THIAZOLE DERIVATIVES FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATORY DISEASES
Title (de)
5-(4-METHANSULFONYL-PHENYL)-THIAZOL-DERIVATE ZUR BEHANDLUNG VON AKUTEN UND CHRONISCHEN ENTZÜNDUNGSERKRANKUNGEN
Title (fr)
DÉRIVÉS DE 5-(4-METHANESULFONYL-PHENYL)-THIAZOLE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES AIGUËS ET CHRONIQUES
Publication
Application
Priority
- EP 2009057324 W 20090615
- EP 08380177 A 20080616
- US 13966108 A 20080616
- EP 09765806 A 20090615
Abstract (en)
[origin: WO2009153226A1] The invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, in the preparation of a medicament for the treatment of an acute or chronic inflammatory disease, by inhibiting the production of at least one pro-inflammatory cytokine selected from TNF-alpha and IFN-gamma, or by inmunomodulating the IL-8 chemokine and/or the IL-10 regulatory cytokine. The invention also relates to novel compounds of formula (I') or a pharmaceutically acceptable salt, prodrug and/or solvate thereof, as well as a pharmaceutical composition comprising said compound.
IPC 8 full level
C07D 277/24 (2006.01); A61K 31/425 (2006.01)
CPC (source: EP KR)
A61K 31/425 (2013.01 - EP); A61K 31/426 (2013.01 - KR); A61P 1/04 (2017.12 - EP); A61P 1/16 (2017.12 - EP); A61P 3/00 (2017.12 - EP); A61P 3/08 (2017.12 - EP); A61P 7/00 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 11/02 (2017.12 - EP); A61P 11/06 (2017.12 - EP); A61P 13/08 (2017.12 - EP); A61P 13/10 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 17/00 (2017.12 - EP); A61P 17/04 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 19/04 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/02 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/04 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 37/08 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 277/24 (2013.01 - EP KR); C07D 277/34 (2013.01 - EP)
Citation (search report)
See references of WO 2009153226A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA RS
DOCDB simple family (publication)
WO 2009153226 A1 20091223; AR 072113 A1 20100804; AU 2009259451 A1 20091223; AU 2009259451 B2 20130314; BR PI0915325 A2 20151027; CA 2728139 A1 20091223; CN 102083806 A 20110601; CO 6331429 A2 20111020; EP 2313382 A1 20110427; IL 209801 A0 20110228; JP 2011524352 A 20110901; KR 20110022679 A 20110307; MA 32473 B1 20110703; MX 2010013978 A 20110329; NZ 589894 A 20110826; RU 2011101439 A 20120727; RU 2495031 C2 20131010; SA 109300384 B1 20130420; TW 201010988 A 20100316; TW I403506 B 20130801; UY 31896 A 20100129; ZA 201008877 B 20120229
DOCDB simple family (application)
EP 2009057324 W 20090615; AR P090102121 A 20090612; AU 2009259451 A 20090615; BR PI0915325 A 20090615; CA 2728139 A 20090615; CN 200980122682 A 20090615; CO 11003796 A 20110114; EP 09765806 A 20090615; IL 20980110 A 20101206; JP 2011513001 A 20090615; KR 20117001228 A 20090615; MA 33516 A 20110113; MX 2010013978 A 20090615; NZ 58989409 A 20090615; RU 2011101439 A 20090615; SA 109300384 A 20090615; TW 98118927 A 20090606; UY 31896 A 20090612; ZA 201008877 A 20101209